Updates on cytochrome P450-mediated cardiovascular drug interactions.

Abstract

Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes.When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with significant clinical consequences may occur. This review discusses CYP450-mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced significant cardiovascular side effects. The principles in predicting drug interactions are also discussed.

• Authors: Judy W M Cheng, William H Frishman, Wilbert S Aronow
• Journal: American journal of therapeutics (Am J Ther) 2009 Mar-Apr Vol. 16 Issue 2 Pg. 155-63 ISSN: 1536-3686 [Electronic] United States
• PMID: 19114873 (Publication Type: Journal Article, Review)

Chemical References

• Cardiovascular Agents
• Enzyme Inhibitors
• Pharmaceutical Preparations
• Cytochrome P-450 Enzyme System

Topics

• Cardiovascular Agents (adverse effects, pharmacokinetics, pharmacology)
• Cardiovascular Diseases (drug therapy, metabolism)
• Cytochrome P-450 Enzyme System (drug effects, metabolism)
• Drug Interactions
• Enzyme Induction (drug effects)
• Enzyme Inhibitors (pharmacology)
• Humans
• Pharmaceutical Preparations (metabolism)